DRUG DISCOVERY AND EVALUATION SAFETY AND PHARMACOKINETIC ASSAYS 3 VOL SET 3ED (HB 2024)

Many aspects of drug safety have become an outstanding and even persistent issue and may occur during the process of both drug discovery and development. Until 15 years ago, drug discovery and evaluation was primarily a sequential process starting with the selection of the most pharmacologically active compound from a series of newly synthesized small molecule chemical series by means of distinctive pharmacological assays. Safety aspects were addressed by evaluation of the selected compound at high doses in a series of specific studies directed at indications other than the intended indication of the new compound. These tests are then followed by pharmacokinetic studies, which are primarily conducted to confirm whether the selected compound possesses a suitable half-life for sufficient exposure and efficacy and whether it has the desired properties specificity to the intended route of administration. Safety aspects relied predominantly on the conduct of single and repeat-dose toxicity studies, which inform changes in organ structure rather than organ function. Both toxicological and pharmacokinetic studies are adapted to the progress of studies in clinical pharmacology and clinical trials. The new edition of this well and broadly accepted reference work contains several innovative and distinguished chapters.

 This "sequential" strategy has been abandoned with this new version of the book for several reasons:

 - Of the possible multitude of negative effects that novel drugs may impart on organ function, e.g. ventricular tachy-arrhythmia, many are detected too late in non-clinical studies to inform clinicians. On the other hand, negative findings in chronic toxicity studies in animals may turn out to be irrelevant for human beings.

 - New scientific approaches, e.g. high-throughput screening, human pluripotent stem cells, transgenic animals, knock-out animals, in silico models, pharmaco-genomics and pharmaco-proteomics, as well as Artificial Intelligence (AI) methods offered new possibilities.

 - There are several examples, that show that the "druggability" of compounds was considerably underestimated when the probability of success of a new project was assessed.

 The success rate in the pharmaceutical industry and the introduction of new chemical entities to the market per year dropped dramatically, whereas the development time for a new compound increased, sometimes exceeding the patent protection. Research and development scientists, involving the following changes, therefore adopted a change of strategy:

 - Parallel instead of sequential involvement of the various disciplines (multidimensional compound optimization).

 - The term "Safety Pharmacology" was coined. The International Conference on Harmonization (ICH) founded a Safety Pharmacology Working Group and the Safety Pharmacology Society (SPS) was launched. The discipline provided for evaluation, development and validation of a multitude of safety tests outlined in the 'Core Battery of Studies'.

 - Characterizing the exposure profile of a drug by conducting pharmacokinetic studies that evaluates the absorption, distribution, metabolism and excretion should be investigated at an early stage of development as results contribute to the selection of a compound for further development.

 Advancements in Toxicology were achieved by the introduction of new methods, e.g., in silico methods, genetic toxicology, computational toxicology and AI.

 The book is a landmark in the continuously changing world of drug research and developments. As such, it is essential reading for many groups: not only for all students of pharmacology and toxicology but also for industry scientists and physicians, especially those involved in clinical trials of drugs, and for pharmacists who must know the safety requirements of drugs.

 The book is essential for scientists and managers in the pharmaceutical industry who are involved in drug discovery, drug development and decision making in the development process.

 In particular, the book will be of use to government institutions and committees working on official guidelines for drug evaluation worldwide.

Franz J. Hock Since retiring from Aventis in 2002, Dr. Hock has leveraged his experience as freelance consultant specializing in Safety Pharmacology. Dr. Hock was a research scientist at Hoechst, Hoechst Marion Roussel, and Aventis from 1976 to 2002. He initially worked on methods in general pharmacology and nephrology, before becoming Head of a Laboratory devoted to pharmacological methods for drugs influencing memory and learning. He was ultimately Head of Laboratory for General/Safety Pharmacology at the Frankfurt site of Aventis Pharma Deutschland GmbH. Dr. Hock received his MSc in Neurobiology from the Technical University Darmstadt and his DSc in Zoology from the University of Kassel, Department of Biology, Institute of Neuroethology and Biocybernetics.

He received the degree of Fachpharmakologe DGPT (“certified expert pharmacology”) in 1981. In 1983 he spent a sabbatical year at the University of California, Irvine, at the Center for the Neurobiology of Learning and Memory (Director Prof. Dr. James L. McGaugh). He lectured for several years to students in Biology at the University of Kassel and the Technical University of Darmstadt. He has published over 100 original papers on methods in pharmacology and on new compounds.

He is currently a member of the “Task Force General/Safety Pharmacology German/Swiss Pharmaceutical Companies.” A member of several national and international scientific societies, Dr. Hock is a founding member of “Safety Pharmacology Society,” “Neurowissenschaftliche Gesellschaft e.V.,” and “European Behavioural

Pharmacology Society.” He served several years as a member of the Program Committee and the Academic Outreach Committee of the Safety Pharmacology Society. He is member of several domestic and international scientific societies.

Michael K. Pugsley Dr. Pugsley is the Senior Director of Toxicology & Safety Pharmacology at Cytokinetics Inc., where he currently designs, manages, interprets, and reports the findings from all nonclinical IND- and NDA-enabling toxicology studies for therapeutic areas including Heart Failure and Amyotrophic Lateral Sclerosis (ALS). Additionally, he leads the in-house conduct of all non-GLP toxicology studies for several discovery biology programs. He also provides high-level expertise to project and program teams and senior management, including evaluation of study conclusions and the potential impact of study results on programand clinical/regulatory strategy. He is a subject matter expert in the discovery, development, and safety characterization of both small molecules and biologics in Cardiovascular, Diabetes, Neurological, and Immunological therapeutic areas. He also is involved in the preparation of all nonclinical documents for regulatory (US, EU, Japan, and China) agency interactions and submissions.

He received his doctorate in Pharmacology & Therapeutics from The University of British Columbia, Vancouver, BC, Canada, and was a postdoctoral fellow at The University of California, Irvine in the Department of Molecular Genetics & Microbiology. Dr. Pugsley is a Fellow (FBPhS) of the British Pharmacology Society and a Diplomat (DSP) and Past President of the Safety Pharmacology Society (SPS). Michael has been working in the Pharmaceutical Industry for 25 years and is the author of 155 publications including 134 peer-reviewed articles, 21 book chapters, and 5 books. He is also a member of the American College of Toxicology, Society of Toxicology, American Heart Association, and Heart Failure Society of America.